<DOC>
	<DOC>NCT00648648</DOC>
	<brief_summary>This study will investigate MK1775 alone and in combination with one of the following three drugs: gemcitabine, cisplatin, and carboplatin in patients with advanced solid tumors. The purpose of the study is to test safety and tolerability of MK1775 alone and in combination, and to find the maximum tolerated dose (MTD) of MK1775 as monotherapy and in combination therapy.</brief_summary>
	<brief_title>A Dose Escalation Study of MK1775 in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adults With Advanced Solid Tumors (MK-1775-001 AM7)</brief_title>
	<detailed_description />
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Subject must have a histologically confirmed metastatic or locally advanced solid tumor, progressed despite standard therapy, or for which standard therapy does not exist Subject is at least 18 years old Subject must have performance status of &lt;=1 on the ECOG Performance Scale Female subjects must not be pregnant Subject has had chemotherapy, radiotherapy, or biological therapy within 4 weeks prior to entering the study or who has not recovered from adverse events due to agents given more than 4 weeks earlier Subject is participating or has participated in a study with an investigational compound or device within 30 days Subjects with active CNS metastases and/or carcinomatous meningitis are excluded. However, subjects with CNS metastases who have completed a course of therapy would be eligible for the study provided they are clinically stable for 1 month prior to entry Subject with a primary central nervous system tumor Subject is allergic to any of the components of the combination study therapy or its analogs Participant has had prescription or nonprescription drugs or other products known to be metabolized by CYP3A4 that cannot be discontinued prior to Day 1 of dosing and withheld throughout the study until 2 weeks after the last dose of study medication. Medications of particular concern are inhibitors of CYP3A4 (azole antifungals [ketoconazole, itraconazole], macrolide antibiotics [erythromycin, clarithromycin], cimetidine, aprepitant, HIV protease inhibitors, nefrazodone, and the following inducers of CYP3A4: phenytoin, barbiturates and rifampicin, and substrates of CYP3A4 including statins (lovastatin, simvastatin), midazolam, terfenadine, astemizole, and cisapride Subject is a regular user (including "recreational use") of any illicit drugs or had a recent history (within the last year) of drug or alcohol abuse Subject is pregnant or breastfeeding, or expecting to get pregnant during the time the study will be ongoing Subject is (HIV)positive Subject has a history of Hepatitis B or C Subject has symptomatic ascites or pleural effusion. A subject who is clinically stable following treatment for these conditions is eligible Subject must not have prior radiation therapy to more than 30% of the bone marrow and must have recovered for at least 3 weeks from the hematologic toxicity of prior radiotherapy Subject has had a prior stem cell or bone marrow transplant Subject has received more than 4 prior cytotoxic chemotherapy regimens Participant has a history suggestive of LiFraumeni Syndrome</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>